Therapy Detail

Therapy Name Anlotinib
Therapy Description

Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, thereby preventing angiogenesis and tumor cell growth (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Anlotinib AL3818|AL-3818 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, thereby preventing angiogenesis and tumor cell growth (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown sarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in partial response in 14% (22/154) of patients with soft tissue sarcomas, with a median progression free survival of 5.63 months, and a disease progression free rate at 12 weeks of 57% (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown fibrous histiocytoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 5% (1/19) and a disease progression free rate at 12 weeks of 47% (9/19) in patients with malignant fibrous histiocytoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown Advanced Solid Tumor not applicable Anlotinib Phase I Actionable In a Phase I trial, Anlotinib (AL-3818) treatment resulted in partial response in 15% (3/20) and stable disease in 70% (14/20) of patients with advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr e13586)). detail...
Unknown unknown alveolar soft part sarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 46% (6/13) and a disease progression free rate at 12 weeks of 77% (10/13) in patients with alveolar soft part sarcoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown leiomyosarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 8% (2/26) and a disease progression free rate at 12 weeks of 69% (18/26) in patients with leiomyosarcoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown liposarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 8% (1/13) and a disease progression free rate at 12 weeks of 54% (7/13) in patients with liposarcoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown synovial sarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 13% (6/47) and a disease progression free rate at 12 weeks of 64% (30/47) in patients with synovial sarcoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Unknown unknown fibrosarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) resulted in an overall response rate of 11% (2/18) and a disease progression free rate at 12 weeks of 61% (11/18) in patients with fibrosarcoma (J Clin Oncol 34, 2016 (suppl; abstr 11005)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Recruiting